BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL.
Gonçalves A, et al. Among authors: gilabert m.
Ann Oncol. 2012 Nov;23(11):2799-2805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5.
Ann Oncol. 2012.
PMID: 22771827
Free article.
Clinical Trial.